Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches

PLoS Computational Biology

Volumn 2, Issue 12, 2006, Pages 1649-1662

  Mac Gabhann, Feilim ^a   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; CELL ENGINEERING; CELL SIGNALING; COMPUTATION THEORY; COMPUTATIONAL METHODS; DISEASES; ENDOTHELIAL CELLS; SIGNALING;

ANGIOGENESIS; BLOCKINGS; COMPUTATIONAL MODELLING; IN-VIVO; ISOFORMS; NEO-VASCULARIZATION; NEUROPILINS; PATHOLOGICAL CONDITIONS; PHYSIOLOGICAL CONDITION; VASCULAR ENDOTHELIAL GROWTH FACTOR;

TUMORS;

NEUROPILIN 1; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ARTICLE; BREAST CANCER; COMPUTER SIMULATION; GEOMETRY; IN VITRO STUDY; IN VIVO STUDY; KINETICS; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; PROTEIN TRANSPORT; TISSUE SPECIFICITY; BIOLOGICAL MODEL; BIOLOGY; COMPARATIVE STUDY; DRUG ANTAGONISM; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; KINETICS; MODELS, BIOLOGICAL; NEOPLASMS; NEUROPILIN-1; PROTEIN BINDING; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846025118     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.0020180     Document Type: Article

References (50)

1. Idris NM, Haider H, Goh MW, Sim EK (2004) Therapeutic angiogenesis for treatment of peripheral vascular disease. Growth Factors 22: 269-279.
2. Rajagopalan S, Mohler ER III, Lederman RJ, Mendelsohn FO, Saucedo JF, et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938.
3. Dy GK, Adjei AA (2006) Angiogenesis inhibitors in lung cancer: A promise fulfilled. Clin Lung Cancer 7 (Supplement 4): S145-S149.
4. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132.
5. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, et al. (2002) Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem 277: 11410-11415.
6. Cheng L, Jia H, Lohr M, Bagherzadeh A, Holmes DI, et al. (2004) Antichemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. J Biol Chem 279: 30654-30661.
7. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - In control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
8. ShibuyaM, Claesson-Welsh L (2006) Signal transduction byVEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560.
9. Mac Gabhann F, Popel AS (2005) Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: A computational model. Am J Physiol Heart Circ Physiol 288: H2851-H2860.
10. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85: 357-368.
11. Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, et al. (2004) VEGF164(165) as the pathological isoform: Differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45: 368-374.
12. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, et al. (1998) Differential expression of vascular endothelial growth factor mRNA versus protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77: 2120-2128.
13. Mac Gabhann F, Popel AS (2004) Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 286: H153-H164.
14. Whitaker GB, Limberg BJ, Rosenbaum JS (2001) Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem 276: 25520-25531.
15. Oh H, Takagi H, Otani A, Koyama S, Kemmochi S, et al. (2002) Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): A mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci U S A 99: 383-388.
16. Bernatchez PN, Rollin S, Soker S, Sirois MG (2002) Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem 85: 629-639.
17. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, et al. (1998) Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273: 22272-22278.
18. Soker S, Fidder H, Neufeld G, Klagsbrun M (1996) Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271: 5761-5767.
19. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
20. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, et al. (1997) Neuropilin is a semaphorin III receptor. Cell 90: 753-762.
21. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, et al. (2002) Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem277: 18069-18076.
22. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, et al. (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277: 24818-24825.
23. Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, et al. (1998) Neuropilin-2 is a receptor for semaphorin IV: Insight into the structural basis of receptor function and specificity. Neuron 21: 1079-1092.
24. Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, et al. (2005) A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 92: 328-333.
25. Mac Gabhann F, Ji JW, Popel AS (2006) Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol 2 (9): e127.
26. Mac Gabhann F, Ji JW, Popel AS (2006) VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol. epub 12 October 2006.
27. Mac Gabhann F, Popel AS (2006) Interactions of VEGF isoforms with VEGFR1, VEGFR2 and Neuropilin in vivo: A computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol. doi:10.1152/ajpheart.00637.2006
28. Chalmers JJ, Zborowski M, Moore L, Mandal S, Fang BB, et al. (1998) Theoretical analysis of cell separation based on cell surface marker density. Biotechnol Bioeng 59: 10-20.
29. Less JR, Skalak TC, Sevick EM, Jain RK (1992) Microvascular network architecture in a mammary carcinoma. EXS 61: 74-80.
30. Less JR, Skalak TC, Sevick EM, Jain RK (1991) Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions. Cancer Res 51: 265-273.
31. Olewniczak S,Chosia M,KolodziejB,KwasA,KramA, et al. (2003)Angiogenesis as determined by computerised image analysis and the risk of early relapse in women with invasive ductal breast carcinoma. Pol J Pathol 54: 53-59.
32. Olewniczak S, Chosia M, Kwas A, Kram A, Domagala W (2002) Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol 53: 183-188.
33. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 52: 1592-1597.
34. Paran Y, Bendel P, Margalit R, Degani H (2004) Water diffusion in the different microenvironments of breast cancer. NMR Biomed 17: 170-180.
35. Belien JA, Somi S, de Jong JS, van Diest PJ, Baak JP (1999) Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J Clin Pathol 52: 184-192.
36. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955.
37. Garvin S, Dabrosin C (2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63: 8742-8748.
38. Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231: 113-122.
39. Magalhães J, Ascensão A, Marques F, Soares J, Neuparth M, et al. (2005) Skeletal muscle ultrastructural and plasma biochemical signs of endothelium dysfunction induced by a high-altitude expedition (Pumori, 7161 m). Basic Appl Myol 15: 29-35.
40. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163: 1801-1815.
41. Filion RJ, Popel AS (2004) A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Ann Biomed Eng 32: 645-663.
42. Dabrosin C, Margetts PJ, Gauldie J (2003) Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer 107: 535-540.
43. Dabrosin C, Chen J, Wang L, Thompson LU (2002) Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 185: 31-37.
44. Dabrosin C (2005) Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res 11: 8036-8041.
45. Fuh G, Garcia KC, de Vos AM (2000) The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 275: 26690-26695.
46. Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G (2001) Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem 276: 18688-18694.
47. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943.
48. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62.
49. Stephenson JM, Banerjee S, Saxena NK, Cherian R, Banerjee SK (2002) Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast:Apossible marker for the progression of breast cancer. Int J Cancer 101: 409-414.
50. Nahta R, Esteva FJ (2006) Herceptin: Mechanisms of action and resistance. Cancer Lett 232: 123-138.